Clinical Trial

Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This investigator-initiated trial aims to evaluate the safety and efficacy of universal anti-CD70 CAR-T (CHT101) in patients with relapsed refractory systemic lupus erythematosus.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-20; most recent amendment 2026-06-24.
Status change: Not Yet Recruiting → Recruiting 2025-09-29
Trial Details
NCT Number NCT06946485
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions Systemic Lupus Erythematosus (SLE)
Enrollment 15 participants
Start Date 2025-04-02
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-29